HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,105.00
+130.00 (4.37%)
Jun 9, 2026, 3:30 PM KST
Market Cap362.50B -53.5%
Revenue (ttm)51.51B +46.5%
Net Income-50.45B
EPS-413.72
Shares Out 121.85M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume247,535
Open2,975.00
Previous Close2,975.00
Day's Range2,975.00 - 3,180.00
52-Week Range2,960.00 - 6,020.00
Beta-0.03
Analystsn/a
Price Targetn/a
Earnings DateAug 14, 2026

About COSE:PKME.N0000

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements